1. |
- Talvik, M, et al.
(författare)
-
A cross-validation study on the relationship between central D-2 receptor occupancy and serum perphenazine concentration
- 2004
-
Ingår i: Psychopharmacology. - Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden. Glostrup Univ Hosp, Dept Clin Biochem, Glostrup, Denmark. : SPRINGER. - 0033-3158 .- 1432-2072. ; 175:2, s. 148-153
-
Tidskriftsartikel (refereegranskat)abstract
- Rationale: There is a need for laboratory measures to guide clinical treatment with antipsychotic drugs. For serum concentration of the classical antipsychotic drug perphenzine an optimal therapeutic interval has been identified between 2 and 6 nmol/l. Positron emission tomography (PET) studies have suggested an optimal interval in central dopamine D-2 receptor occupancy of between 65 and 80%. Objectives: The aim of the present cross-validation study in clinically stable schizophrenic patients was to examine the relationship between the optimal interval in central D-2 receptor occupancy and the therapeutic window for serum perphenazine concentration. Methods: Six patients who had responded to maintenance treatment with perphenazine decanoate were examined with PET and [C-11]raclopride during steady-state conditions. Blood sampling was carried out for minimum serum perphenazine concentration and during the PET examination. Results: The serum perphenazine concentration was between 1.8 and 9 nmol/l and the D-2 receptor occupancy varied between 66 and 82%. The relationship between central receptor occupancy and serum drug concentration was curvilinear. Mild extrapyramidal symptoms were present in the patient with the highest D-2 receptor occupancy. Conclusions: The previously suggested therapeutic window in serum perphenazine concentration is in good agreement with the optimal interval suggested for central D-2 receptor occupancy. Serum concentrations at low dose levels may therefore serve as a useful tool in clinical monitoring of antipsychotic drug treatment.
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
|
|